Here are four things to know:
1. Imvexxy is intended to treat moderate-to-severe dyspareunia, or vaginal pain associated with sex. The condition is a symptom of vulvar and vaginal atrophy, which often occurs during menopause when women produce less estrogen.
2. The hormone therapy is administered as a softgel capsule inserted into the vagina and will be available in two doses.
3. Imvexxy contains a black box warning on its label, noting the risk of endometrial and breast cancers, cardiovascular disorders, and probable dementia.
4. TherapeuticsMD plans to conduct a post-approval observational study on the drug’s safety per the FDA’s request.
More articles on supply chain:
How Amazon’s latest patent would let customers interact with delivery drones
Allergan recalls 170k birth control samples with placebo pills in wrong order
Red Cross offers blood donors $5 Amazon gift card to boost summer donations
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
